Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
68.00
Ask:
69.00
Spread: 1.00 (1.471%)
Market Cap: £311.75m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

New OPTIM Software and Hardware

4 Aug 2014 07:00

RNS Number : 0911O
Avacta Group PLC
04 August 2014
 



4 August 2014

Avacta Group plc

("Avacta" or the "Group")

 

 

New OPTIM Software and Hardware

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Avacta Analytical has completed the development of two new OPTIM variants. Alongside this, the Group has released upgraded OPTIM software, intended to widen the range of potential customers. 

OPTIM, Avacta Analytical's protein characterisation instrument, was launched during 2010 as OPTIM 1000 and was substantially redeveloped into the OPTIM2 system during 2013. Designed to reduce the time and cost of therapeutic protein development, the OPTIM instruments can provide multiple protein stability-indications at high speed using ultra-low sample volumes.

Avacta has completed the development of upgraded software for the OPTIM platform, expanding the capabilities available to end users. Two new variants to the core OPTIM platform, OPTIM 375 and OPTIM 445, which incorporate incremental measurement capabilities are now available. The Directors consider that these two new variants and the related upgraded software widen the appeal of OPTIM in its core drug development market by focusing on applications to characterise the viscosity of samples and the stability of membrane protein targets.

Alastair Smith, Avacta Group Chief Executive of Avacta said: "Now that OPTIM is becoming established as a valuable tool for protein stability characterisation, we are working hard to expand the range of applications and measurement types that the system can support in order to broaden the instrument's market appeal and drive consumable usage. The latest developments are in response to the market demand, which is growing worldwide, that we have identified for viscosity determination on small samples and for stability characterisation of membrane protein targets which are a challenging but important class of protein samples."

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

Numis Securities Limited

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel: +44 (0) 207 260 1000

www.numiscorp.com

Media Enquiries

Walbrook PR Ltd

Mike Wort / Anna Dunphy

Tel: +44 (0) 207 933 8780

avacta@walbrookpr.com

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGGRKMZGDZM
Date   Source Headline
25th Apr 20074:29 pmPRNHolding(s) in Company
10th Apr 200711:59 amPRNDirector Shareholding
5th Apr 200712:13 pmPRNTotal Voting Rights
4th Apr 20077:00 amPRNPlacing and Appointment of joint broker
4th Apr 20077:00 amPRNProduct Launch
30th Jan 20071:51 pmPRNInterim Results
21st Dec 20068:44 amPRNTotal Voting Rights
29th Nov 20067:00 amPRNRe Agreement
20th Oct 20063:40 pmRNSChange of accounting ref date
11th Oct 200611:12 amRNSAnnual Report and Accounts
19th Sep 20067:00 amPRNRe Agreement
24th Aug 20067:00 amPRNCollaboration Agreement
9th Aug 20068:03 amPRNSupplementary consideration shares
8th Aug 20068:00 amPRNFirst Day of Dealings
7th Aug 200612:58 pmRNSResult of EGM
21st Jul 200610:15 amRNSSch 1 - Readybuy PLC
14th Jul 20062:20 pmRNSFinal Results
14th Jul 200612:00 pmRNSRestoration - Readybuy PLC
14th Jul 200612:00 pmRNSPropsd Aqstn & notice of EGM
13th Jul 20069:30 amRNSStmnt re Proposed Transaction
13th Jul 20068:05 amRNSSuspension - Readybuy PLC
7th Jul 20064:07 pmRNSDirectorate Change
5th May 200611:24 amRNSResult of EGM
19th Apr 20063:13 pmRNSFurther re Issue of Equity
19th Apr 20068:08 amRNSHolding(s) in Company
13th Apr 20065:28 pmRNSHolding(s) in Company
12th Apr 20067:44 amRNSIssue of Equity
9th Mar 20062:19 pmRNSHolding(s) in Company
26th Jan 20068:23 amRNSInterim Results
24th Aug 20057:00 amRNSFinal Results
25th Jul 20057:57 amRNSBoard change & trading update
17th Jun 200511:09 amRNSBusiness Strategy
25th May 20054:55 pmRNSIssue of Equity
11th Apr 200511:00 amRNSEGM Statement
23rd Mar 20059:22 amRNSIssue of Equity
15th Mar 20053:32 pmRNSNotice of EGM
28th Jan 20054:48 pmRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.